This biorobot leverages synthetic biology to activate antitumor responses in cancer therapy, suggesting new treatment strategies.
Advances in synthetic biology have enabled innovative strategies for cancer therapy, yet precise control of therapeutic expression and biosafety remain critical challenges. To address these issues, a bacterial hybrid biorobot is developed using Escherichia coli (MG1655) engineered for localized activation by microwaves. Upon activation, the biorobot expresses glucose oxidase (GOx) at tumor sites, leading to glucose depletion and hydrogen peroxide generation. Surface-attached Cu2O nanoparticles catalyze this hydrogen peroxide through a Fenton-like reaction, producing reactive oxygen species that drive multiple forms of tumor cell death, including apoptosis, ferroptosis, and cuproptosis. Comprehensive in vitro and in vivo studies confirm the efficacy of this approach, while transcriptomic analysis reveals disruption of glucose metabolism and robust activation of antitumor immune responses. This work demonstrates the potential of this engineered bacterial platform as a safe and versatile tool for precise, multimodal cancer treatment.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: